Bisphosphonates and Dental Treatment

Bisphosphonates and Dental Treatment

A Complete Guide for Dental Practices

Introduction

Modern dental practices increasingly treat patients with complex medical histories. One group of medications that every dental professional must understand is bisphosphonates. These drugs are widely prescribed for osteoporosis, bone metastases, and other metabolic bone diseases, but they carry a significant dental risk — Medication-Related Osteonecrosis of the Jaw (MRONJ).

For dentists, hygienists, therapists, and dental nurses, recognising patients taking bisphosphonates is essential, particularly when planning extractions, implant placement, periodontal surgery, or other invasive procedures.

Bisphosphonates affect bone metabolism and healing. In some patients, especially those receiving long-term or intravenous treatment, trauma to the jaw can lead to bone necrosis that fails to heal. While the condition is rare, the consequences can be severe, requiring long-term management and specialist referral.

This article provides a comprehensive guide for dental teams covering:

  • What bisphosphonates are

  • Common medications used in the UK

  • Why they matter in dentistry

  • Dental risks and complications

  • Signs and symptoms of MRONJ

  • Safe dental management strategies

  • Documentation and patient screening

Understanding these medications allows dental teams to reduce complications, protect patients, and practice safe evidence-based dentistry.

What Are Bisphosphonates?

Bisphosphonates are medications designed to slow bone breakdown. They work by inhibiting osteoclast activity, the cells responsible for bone resorption.

This leads to:

  • Increased bone density

  • Reduced fracture risk

  • Stabilisation of bone metastases

  • Improved skeletal strength in osteoporosis

However, this suppression of bone turnover also reduces the bone's ability to repair itself after trauma, which is where dentistry becomes particularly important.

The jawbones have a very high turnover rate, making them particularly vulnerable to complications when healing is impaired.

Common Bisphosphonates Dental Teams Should Recognise

Dental professionals should be able to recognise commonly prescribed bisphosphonates during medical history checks.

1. Alendronic Acid

Brand examples: Fosamax

Alendronic acid is one of the most commonly prescribed bisphosphonates in the UK and globally.

It is primarily used to treat:

  • Osteoporosis

  • Osteopenia

  • Steroid-induced bone loss

The medication is usually taken weekly in tablet form.

Although the MRONJ risk is relatively low with oral bisphosphonates, it still exists, particularly in patients who have taken the medication for more than 3–5 years.

Dental teams should pay particular attention when patients require extractions or implant placement.

2. Risedronate

Brand examples: Actonel

Risedronate is another oral bisphosphonate prescribed for osteoporosis management, particularly in post-menopausal patients.

It works similarly to alendronic acid and is commonly taken:

  • Weekly

  • Monthly

  • Occasionally daily depending on prescription

Dental considerations are similar to alendronic acid.

While the risk of MRONJ remains low, it increases with:

  • Longer treatment duration

  • Poor oral hygiene

  • Invasive dental procedures

  • Smoking

  • Diabetes

  • Steroid therapy

3. Zoledronic Acid

Zoledronic acid is a much stronger bisphosphonate, typically administered intravenously in hospital settings.

It is commonly used for:

  • Bone metastases from cancers

  • Multiple myeloma

  • Severe osteoporosis

  • Hypercalcaemia of malignancy

From a dental perspective, this medication carries significantly higher MRONJ risk compared with oral bisphosphonates.

Patients receiving IV bisphosphonates require extreme caution before any invasive dental treatment.

In many cases, dentists should consider specialist referral before extractions.

Why Bisphosphonates Are Critical for Dentistry

Dental trauma can trigger Medication-Related Osteonecrosis of the Jaw (MRONJ).

MRONJ occurs when exposed bone in the jaw fails to heal for longer than 8 weeks in a patient with a history of antiresorptive medication.

The condition may develop after:

  • Tooth extraction

  • Implant placement

  • Periodontal surgery

  • Ill-fitting dentures causing trauma

  • Spontaneously without dental treatment

Although uncommon, MRONJ can cause severe complications such as:

  • Chronic pain

  • Infection

  • Exposed bone

  • Pathological fractures

  • Long-term disability

Because of this, dentists must identify at-risk patients before performing procedures.

Medication-Related Osteonecrosis of the Jaw (MRONJ)

MRONJ is a serious but preventable condition if dental teams identify risk factors early.

The mechanism involves:

  1. Suppressed bone turnover

  2. Reduced blood supply

  3. Impaired healing

  4. Infection following trauma

This leads to necrotic bone that becomes exposed in the oral cavity.

The jaw is particularly vulnerable because of:

  • Frequent micro-trauma from chewing

  • Dental infections

  • Tooth extractions

  • Periodontal disease

Signs and Symptoms of MRONJ

Dental professionals should be able to recognise early and advanced signs.

Below is a structured overview of symptoms dental teams should monitor.

Stage Clinical Signs Patient Symptoms Dental Findings
Early Delayed healing after extraction Mild discomfort Slight exposed bone
Early Gingival swelling Sensitivity Inflammation around extraction site
Moderate Persistent exposed bone Pain when chewing Non-healing socket
Moderate Local infection Bad taste or halitosis Pus discharge
Advanced Large areas of necrotic bone Severe pain Visible bone sequestration
Advanced Soft tissue ulceration Difficulty eating Pathological fracture risk
Severe Chronic infection Facial swelling Sinus involvement
Severe Osteomyelitis Numbness of lip or chin Radiographic bone destruction

Recognising early symptoms can allow rapid referral and intervention.

Risk Factors for MRONJ in Dental Patients

Several factors increase the risk of developing osteonecrosis.

Medication-related risks

  • Intravenous bisphosphonates

  • Long duration of therapy (>3 years)

  • High potency drugs

  • Concurrent steroid therapy

Dental risks

  • Tooth extractions

  • Implant placement

  • Periodontal surgery

  • Poor oral hygiene

  • Ill-fitting dentures

Medical risks

  • Cancer

  • Diabetes

  • Smoking

  • Chemotherapy

  • Immunosuppression

Patients with multiple risk factors require careful treatment planning.

Dental Assessment for Patients Taking Bisphosphonates

Every dental appointment should include thorough medication screening.

Dental teams should document:

  • Exact medication name

  • Duration of use

  • Route of administration

  • Reason for prescription

  • Prescribing doctor or specialist

This information helps determine patient risk level.

Example documentation:

Assessment Factor Information to Record
Medication Alendronic acid
Duration 4 years
Route Oral
Indication Osteoporosis
Additional risks Diabetes
Planned dental treatment Extraction UR6

This structured approach improves patient safety.

Dental Treatment Planning for Patients on Bisphosphonates

Dental treatment must be carefully planned to reduce MRONJ risk.

Low-risk patients

Patients taking oral bisphosphonates for less than 3 years without additional risk factors are generally considered lower risk.

Treatment considerations:

  • Routine dentistry acceptable

  • Extractions possible with caution

  • Good post-operative care required

Moderate-risk patients

Patients with:

  • Long-term oral therapy

  • Additional medical conditions

Treatment should involve:

  • Minimising surgical trauma

  • Considering alternative treatments

  • Informed consent regarding MRONJ risk

High-risk patients

Patients receiving IV bisphosphonates require extreme caution.

Recommendations include:

  • Avoid elective extractions if possible

  • Prioritise conservative treatment

  • Specialist referral for complex cases

  • Multidisciplinary communication

Managing Tooth Extractions Safely

Extractions remain the highest risk dental procedure for MRONJ development.

Best practices include:

Pre-treatment measures

  • Comprehensive risk assessment

  • Medical consultation if needed

  • Discuss risks with patient

  • Obtain informed consent

During extraction

  • Use minimally traumatic techniques

  • Smooth sharp bone edges

  • Achieve primary closure when possible

Post-operative care

  • Close follow-up appointments

  • Monitor healing

  • Early intervention if healing delays occur

Preventive Dentistry Is Critical

The best way to manage MRONJ is prevention.

Patients on bisphosphonates should receive strong preventive care including:

  • Regular dental examinations

  • Professional cleaning

  • Early treatment of decay

  • Periodontal disease control

Preventing infections reduces the need for extractions or surgery.

Patient Education for Dental Practices

Patients often do not realise their medication affects dental treatment.

Dental teams should educate patients about:

  • Informing dentists about medications

  • Maintaining excellent oral hygiene

  • Attending regular dental check-ups

  • Reporting delayed healing

Patients undergoing cancer treatment with IV bisphosphonates should ideally have dental clearance before therapy begins.

Communication Between Dentists and Doctors

Good communication between healthcare professionals improves patient safety.

Dentists may need to contact:

  • General practitioners

  • Oncologists

  • Rheumatologists

  • Orthopaedic specialists

This is particularly important when patients require invasive dental treatment.

Key Questions Dental Teams Should Ask

Medical history forms should include medication screening questions such as:

  • Are you taking medication for osteoporosis?

  • Have you ever received IV bone-strengthening medication?

  • How long have you taken the medication?

  • Do you receive hospital infusions?

These questions help identify hidden risk factors.

Quick Reference Table for Dental Teams

Drug Common Use Administration Dental Risk Level
Alendronic acid Osteoporosis Oral tablet Low–moderate
Risedronate Osteoporosis Oral tablet Low–moderate
Zoledronic acid Cancer / bone metastases IV infusion High

This table can be used as a chairside reference for dental teams.

The Importance of Medical History Updates

Medical histories should be updated at every appointment.

Patients may start bisphosphonate therapy after their previous dental visit.

Failing to update records could result in unrecognised MRONJ risk before an extraction.

Future Trends in Dental Medicine

As populations age, more patients will receive medications affecting bone metabolism.

Dentists will increasingly encounter patients taking:

  • Bisphosphonates

  • Denosumab

  • Antiangiogenic drugs

  • Targeted cancer therapies

Understanding medication-related dental complications will become an essential skill for modern dental practices.

Final Thoughts for Dental Professionals

Bisphosphonates are widely prescribed medications that significantly improve bone health, but they present important considerations for dental treatment.

Dental professionals must recognise:

  • The medications involved

  • The risk of MRONJ

  • The importance of medical history screening

  • Safe treatment planning

By identifying at-risk patients early and adopting preventive strategies, dental teams can significantly reduce complications.

Ultimately, safe management relies on knowledge, communication, and careful clinical judgement.

Author: Christian Smith, First Medical Training
Updated for 2026 UK Dental Practice
Category: Dental CPD | Medical Emergencies

Back to Blog